Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 3/20 | 0.58 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.53 |
| ▸ | INSR | P06213 | 1/20 | 0.53 |
| ▸ | IGF1R | P08069 | 1/20 | 0.53 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.53 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.53 |
| ▸ | KIT | P10721 | 4/20 | 0.52 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.50 |
| ▸ | FLT3 | P36888 | 3/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 2/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.47 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18108669 | 0.91 | NTRK1 (0.66) | AURKANTRK1INSRIGF1RAURKB | |
| SCHEMBL18108770 | 0.91 | AURKA (0.61) | AURKANTRK1INSRIGF1RAURKB | |
| SCHEMBL18108695 | 0.90 | AURKA (0.71) | AURKANTRK1INSRIGF1RAURKB | |
| SCHEMBL18108658 | 0.90 | AURKA (0.53) | AURKANTRK1INSRIGF1RAURKB | |
| SCHEMBL18108768 | 0.85 | AURKA (0.58) | AURKANTRK1INSRIGF1RAURKB | |
| SCHEMBL18108646 | 0.85 | HDAC6 (0.52) | AURKANTRK1INSRIGF1RAURKB | |
| Trifluoroacetic Acid SCHEMBL18108683 | 0.84 | AURKA (0.56) | AURKANTRK1INSRIGF1RAURKB | |
| SCHEMBL18120890 | 0.84 | AURKA (0.59) | AURKANTRK1INSRIGF1RAURKB | |
| SCHEMBL18108667 | 0.84 | AURKA (0.57) | AURKANTRK1INSRIGF1RAURKB | |
| SCHEMBL18108567 | 0.83 | AURKA (0.55) | AURKANTRK1INSRIGF1RAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10294207-B2 | Pyrazole derivatives as TNIK, IKKϵ and TBK1 inhibitor and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2019-05-21 | — | — | US | claimed |
| US-20160289196-A1 | PYRAZOLE DERIVATIVES AS TNIK, IKKe AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2016-10-06 | — | — | US | claimed |
| US-10294207-B2 | Pyrazole derivatives as TNIK, IKKϵ and TBK1 inhibitor and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2019-05-21 | — | — | US | disclosed |
| US-10294207-B2 | Pyrazole derivatives as TNIK, IKKϵ and TBK1 inhibitor and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2019-05-21 | — | — | US | disclosed |
| US-20160289196-A1 | PYRAZOLE DERIVATIVES AS TNIK, IKKe AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2016-10-06 | — | — | US | disclosed |
| US-20160289196-A1 | PYRAZOLE DERIVATIVES AS TNIK, IKKe AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2016-10-06 | — | — | US | disclosed |
| US-20160289196-A1 | PYRAZOLE DERIVATIVES AS TNIK, IKKe AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2016-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294207-B2 | Pyrazole derivatives as TNIK, IKKϵ and TBK1 inhibitor and pharmaceutical composition comprising same | TNIK, TNNI3K, TNK1 | AURKA 361/4885NTRK1 254/4885INSR 1627/4885 |
| US-20160289196-A1 | PYRAZOLE DERIVATIVES AS TNIK, IKKe AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | TNIK, TNNI3K, TNK1 | AURKA 374/4885NTRK1 238/4885INSR 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.